News

According to a company statement, sugemalimab was approved for use on unresectable stage III NSCLC patients without disease progression after concurrent or sequential platinum-based chemoradiotherapy. NMPA approved sugemalimab

OrbiMed and Maruho have jointly led the financing round, which has also seen participation from HBM Healthcare Investments, Access Biotechnology, TCG X, Omega Funds, Decheng Capital, Samsara BioCapital,

PreHevbri is said to be the only approved 3-antigen hepatitis B vaccine for adults in the UK. It comprises the three hepatitis B surface antigens, S, pre-S1, and

The new investigational recombinant factor VIII (FVIII) therapy efanesoctocog alfa has been designed to extend protection from bleeds with once-weekly prophylactic dosing for haemophilia A patients. It is

New investor NexPoint led the financing round, which included participation from existing investors Eshelman Ventures, Bristol Myers Squibb, and Kingdon Capital. A convertible note, which was provided by

The new investigational drug, also known as KRP203, is a synthetic, sphingosine 1-phosphate receptor (S1PR) modulator. It has been evaluated in Phase I and Phase II trials for

The companies are seeking approval for the antibody to treat adult patients with prurigo nodularis, which is a chronic inflammatory skin disease that causes extreme itch and skin

To be marketed under the proprietary name fylnetra, pegfilgrastim-pbbk was developed in collaboration with Kashiv Biosciences. Fylnetra is used for the treatment of neutropenia, a condition that occurs

Under the collaboration, the company will use its AI drug discovery platform along with Denali Therapeutics’ expertise across the blood-brain barrier (BBB) and neurodegeneration for identifying therapeutically relevant